mermaid
flowchart LR
  CDC["CDC"] -->|"recommends"| two_dose_series_of_shingles_vaccine["two-dose series of shingles vaccine"]
  shingles_vaccine["shingles vaccine"] -->|"is"| two_dose_series_of_injections_given_2_6_months_apart["two-dose series of injections given 2-6 months apart"]
  recombinant_herpes_zoster_vaccine["recombinant herpes zoster vaccine"] -->|"is effective in"| older_adults["older adults"]
  recombinant_herpes_zoster_vaccine["recombinant herpes zoster vaccine"] -->|"effective regardless of"| immunocompromised_status["immunocompromised status"]
  second_dose_of_recombinant_zoster_vaccine__RZV_["second dose of recombinant zoster vaccine (RZV)"] -->|"increased effectiveness against"| shingles["shingles"]
  study["study"] -->|"published in"| Annals_of_Internal_Medicine["Annals of Internal Medicine"]
  study["study"] -->|"measured effectiveness of"| one_or_more_shingles_vaccine_doses_compared_with_none["one or more shingles vaccine doses compared with none"]
  study["study"] -->|"measured effectiveness of"| two_doses_compared_with_one_dose["two doses compared with one dose"]
  study_population["study population"] -->|"included"| 3_45_million_adults_enrolled_in_Medicare_fee_for_service_between_2007_and_2019["3.45 million adults enrolled in Medicare fee-for-service between 2007 and 2019"]
  primary_outcome["primary outcome"] -->|"was"| contracting_herpes_zoster["contracting herpes zoster"]
  secondary_outcomes["secondary outcomes"] -->|"included"| ophthalmicus["ophthalmicus"]
  secondary_outcomes["secondary outcomes"] -->|"included"| postherpetic_neuralgia["postherpetic neuralgia"]
  one_dose_of_RZV["one dose of RZV"] -->|"had 1-year vaccine effectiveness of"| 56_1_["56.1%"]
  two_doses_of_RZV["two doses of RZV"] -->|"had relative vaccine effectiveness of"| 67_9__compared_with_one_dose["67.9% compared with one dose"]
  two_doses_of_RZV["two doses of RZV"] -->|"more effective than"| one_dose_of_RZV["one dose of RZV"]
  median_time_between_doses["median time between doses"] -->|"was"| approximately_4_5_months["approximately 4.5 months"]
  second_dose_within_2_6_months["second dose within 2-6 months"] -->|"yielded effectiveness of"| 68_1_["68.1%"]
  relative_1_year_effectiveness_of_second_dose["relative 1-year effectiveness of second dose"] -->|"was"| 67_4__for_ophthalmicus["67.4% for ophthalmicus"]
  relative_1_year_effectiveness_of_second_dose["relative 1-year effectiveness of second dose"] -->|"was"| 80_7__for_postherpetic_neuralgia["80.7% for postherpetic neuralgia"]
  one_dose_of_RZV["one dose of RZV"] -->|"had lower effectiveness in"| individuals_aged_85_years_or_older["individuals aged 85 years or older"]
  one_dose_of_RZV["one dose of RZV"] -->|"had similar effectiveness in"| immunocompromised_and_immunocompetent_individuals["immunocompromised and immunocompetent individuals"]
  one_dose_of_RZV["one dose of RZV"] -->|"had lower effectiveness in"| Black_individuals["Black individuals"]
  low_representation["low representation"] -->|"resulted in imprecise estimates for"| Black_and_Hispanic_individuals["Black and Hispanic individuals"]
  Nadja_A__Vielot["Nadja A. Vielot"] -->|"is epidemiologist in"| Department_of_Family_Medicine["Department of Family Medicine"]
  Department_of_Family_Medicine["Department of Family Medicine"] -->|"is part of"| University_of_North_Carolina_School_of_Medicine["University of North Carolina School of Medicine"]
  University_of_North_Carolina_School_of_Medicine["University of North Carolina School of Medicine"] -->|"located in"| Chapel_Hill__North_Carolina["Chapel Hill, North Carolina"]
  Nadja_A__Vielot["Nadja A. Vielot"] -->|"affiliated with"| University_of_North_Carolina_School_of_Medicine["University of North Carolina School of Medicine"]
  Shirin_Mazumder__MD["Shirin Mazumder, MD"] -->|"is"| infectious_diseases_specialist["infectious diseases specialist"]
  Shirin_Mazumder__MD["Shirin Mazumder, MD"] -->|"is"| associate_professor["associate professor"]
  Shirin_Mazumder__MD["Shirin Mazumder, MD"] -->|"affiliated with"| University_of_Tennessee_Health_Science_Center["University of Tennessee Health Science Center"]
  University_of_Tennessee_Health_Science_Center["University of Tennessee Health Science Center"] -->|"located in"| Memphis__Tennessee["Memphis, Tennessee"]
  barriers_to_vaccination["barriers to vaccination"] -->|"include"| problems_with_access["problems with access"]
  barriers_to_vaccination["barriers to vaccination"] -->|"include"| lack_of_insurance["lack of insurance"]
  barriers_to_vaccination["barriers to vaccination"] -->|"include"| concerns_about_side_effects["concerns about side effects"]
  potential_solutions["potential solutions"] -->|"include"| establishing_reminder_systems["establishing reminder systems"]
  potential_solutions["potential solutions"] -->|"include"| improving_convenience_and_accessibility["improving convenience and accessibility"]
  potential_solutions["potential solutions"] -->|"include"| promoting_vaccine_programs_that_reduce_financial_burdens["promoting vaccine programs that reduce financial burdens"]
  potential_solutions["potential solutions"] -->|"include"| having_open_conversations_with_patients_regarding_hesitancy["having open conversations with patients regarding hesitancy"]
  study["study"] -->|"supported by"| National_Center_for_Advancing_Translational_Science["National Center for Advancing Translational Science"]
  recombinant_zoster_vaccine__RZV_["recombinant zoster vaccine (RZV)"] -->|"is"| recombinant_herpes_zoster_vaccine["recombinant herpes zoster vaccine"]
  live_zoster_vaccine["live zoster vaccine"] -->|"is different from"| recombinant_zoster_vaccine__RZV_["recombinant zoster vaccine (RZV)"]
  vaccine_effectiveness["vaccine effectiveness"] -->|"was lower in"| racial_groups_such_as_Black_individuals["racial groups such as Black individuals"]
  research["research"] -->|"should investigate"| factors_contributing_to_disparities_in_vaccine_effectiveness_among_racial_groups["factors contributing to disparities in vaccine effectiveness among racial groups"]
